Earnings summaries and quarterly performance for PUMA BIOTECHNOLOGY.
Executive leadership at PUMA BIOTECHNOLOGY.
Board of directors at PUMA BIOTECHNOLOGY.
Research analysts who have asked questions during PUMA BIOTECHNOLOGY earnings calls.
MF
Marc Frahm
TD Cowen
3 questions for PBYI
Also covers: ADAP, AGIO, BPMC +7 more
DR
Divya Rao
TD Cowen
2 questions for PBYI
Also covers: AGIO, APLS, VRTX +1 more
JH
Jiayi He
Barclays
2 questions for PBYI
EW
Edward White
H.C. Wainwright & Co.
1 question for PBYI
Also covers: CRIS, DVAX, GLYC +5 more
Gena Wang
Barclays
1 question for PBYI
Also covers: ALNY, BCRX, BLUE +12 more
MF
Mark Forham
TD Cowen
1 question for PBYI
Recent press releases and 8-K filings for PBYI.
Puma Biotechnology Announces Q3 2025 Earnings and Updates Full-Year Guidance
PBYI
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Puma Biotechnology reported Q3 2025 total revenue of $54.5 million and GAAP net income of $8.8 million, or $0.18 per basic share.
- Net Nerlynx product revenue for Q3 2025 was $51.9 million, an increase from Q2 2025, with 2,949 bottles sold.
- The company updated its full-year 2025 guidance, projecting net Nerlynx product revenue of $198-$200 million and net income of $27-$29 million.
- For Q4 2025, Puma anticipates net Nerlynx product revenue of $54-$56 million and net income between $9-$11 million.
- Clinical trials for alisertib are progressing, with the Aliska Breast I Phase 2 trial enrolling 98 patients and an interim analysis expected in H1 2026, and the Aliska Lung I Phase 2 trial enrolling 61 patients with additional interim data also expected in H1 2026.
Nov 6, 2025, 9:30 PM
Puma Biotechnology Reports Q3 2025 Earnings with Increased Revenue and Updated Guidance
PBYI
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Puma Biotechnology reported total revenue of $54.5 million for Q3 2025, with product revenue net from Nerlynx sales reaching $51.9 million, an increase from $49.2 million in Q2 2025.
- The company achieved GAAP net income of $8.8 million ($0.18 per basic share) and non-GAAP net income of $10.5 million ($0.21 per basic and diluted share) in Q3 2025, up from $5.9 million in Q2 2025.
- Nerlynx bottle sales increased to 2,949 bottles in Q3 2025, up by 341 bottles from Q2 2025, with an estimated inventory increase of 172 bottles.
- Puma Biotechnology updated its full-year 2025 guidance, anticipating net Nerlynx product revenue between $198 million and $200 million (higher than prior guidance) and net income between $27 million and $29 million.
- The company ended Q3 2025 with approximately $94 million in cash, cash equivalents, and marketable securities and reduced its outstanding principal debt balance to approximately $33 million.
Nov 6, 2025, 9:30 PM
Puma Biotechnology Reports Q3 2025 Financial and Operational Results
PBYI
Earnings
Revenue Acceleration/Inflection
- Puma Biotechnology reported NERLYNX net revenue of $51.9 million in Q3 2025, marking an 8% decrease compared to Q3 2024 but a 6% increase from Q2 2025.
- 2,949 ex-factory bottles of NERLYNX were sold in Q3 2025, representing an 8% increase over Q3 2024 and a 13% increase compared to Q2 2025.
- Approximately 77% of patients starting NERLYNX in Q3 2025 did so at a reduced dose.
- Inventory change for Q3 2025 was $3.1 million and 182 bottles.
Nov 6, 2025, 9:30 PM
Puma Biotechnology Reports Q3 2025 Earnings and Updates Full-Year Guidance
PBYI
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Puma Biotechnology reported total revenue of $54.5 million for Q3 2025, with Nerlynx product revenue net at $51.9 million, an increase from $49.2 million in Q2 2025 but a decrease from $56.1 million in Q3 2024. U.S. net sales of Nerlynx were $51.8 million in Q3 2025, up from $48.8 million in Q3 2024.
- The company posted a GAAP net income of $8.8 million ($0.18 per basic share) and a non-GAAP net income of $10.5 million ($0.21 per basic and diluted share) for Q3 2025.
- Puma Biotechnology updated its full-year 2025 guidance, projecting net Nerlynx product revenue between $198 million and $200 million (higher than prior guidance) and net income in the range of $27 million to $29 million. For Q4 2025, net product revenue is anticipated to be $54 million to $56 million and net income $9 million to $11 million.
- Enrollment in the ALISCA-Breast1 trial reached 98 patients, with a formal interim analysis expected in the first half of 2026. The ALISCA-Lung1 study is also enrolling patients, with additional interim data anticipated in the first half of 2026.
Nov 6, 2025, 9:30 PM
Puma Biotechnology Reports Q3 2025 Financial Results and Raises Full Year 2025 Estimates
PBYI
Earnings
Guidance Update
- Puma Biotechnology reported Q3 2025 product revenue, net of $51.9 million, a decrease from $56.1 million in Q3 2024, contributing to total revenue of $54.5 million.
- GAAP net income for Q3 2025 was $8.8 million, or $0.17 per diluted share, compared to $20.3 million, or $0.41 per diluted share, in Q3 2024.
- The company's cash, cash equivalents, and marketable securities totaled $94.4 million as of September 30, 2025.
- Puma Biotechnology raised its 2025 NERLYNX revenue and net income estimates, with updated full year 2025 total revenue guidance of $220-$223 million and net income guidance of $27-$29 million.
Nov 6, 2025, 9:16 PM
Puma Biotechnology Reports Q3 2025 Financial Results
PBYI
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Puma Biotechnology reported total revenue of $54.5 million and GAAP net income of $8.8 million for the third quarter ended September 30, 2025.
- For the first nine months of 2025, total revenue was $152.9 million and GAAP net income was $17.7 million, compared to $171.4 million and $11.0 million, respectively, for the first nine months of 2024.
- The company is raising its 2025 NERLYNX® revenue and net income estimates, with updated full-year 2025 total revenue projected to be $220-$223 million and net income $27-$29 million.
- Product revenue for Q3 2025 decreased year-over-year due to lower international sales, partially offset by an 8% increase in bottles of NERLYNX sold in the U.S. market.
- As of September 30, 2025, Puma Biotechnology had cash, cash equivalents and marketable securities of $94.4 million.
Nov 6, 2025, 9:05 PM
Quarterly earnings call transcripts for PUMA BIOTECHNOLOGY.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more